Skip to main content
INTS
NASDAQ Life Sciences

Q3 Loss Widens to $3.5M as Cash Drops to $8.5M; Two Trials Resume Enrollment

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$3.25
Mkt Cap
$11.427M
52W Low
$3
52W High
$15.748
52W Position info
8.3% above low
Off High info
79% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

INTS is trading near its 52-week low of $3 (8.3% above the low) on light trading volume (0.3× avg).

Summary

Intensity Therapeutics posted a Q3 2026 net loss of $3.5M, wider than the $2.7M loss a year earlier on higher R&D costs, with cash down to $8.5M at September 30. The company raised only $1.5M net through its ATM in the quarter, and the release gives no cash runway estimate — with a going-concern warning already on the books, further financing looks likely. The clinical side is the brighter story: enrollment resumed in the Phase 3 INVINCIBLE-3 sarcoma study and the Phase 2 INVINCIBLE-4 breast cancer study, and preliminary data from 14 INVINCIBLE-4 patients showed pCR rates of 71% and 42% in the two cohorts. Those numbers come from just seven patients per cohort, so they are early and need confirmation. INVINCIBLE-4 enrollment is targeted for completion by end-2027, with an independent safety review planned for Q1 2027.

At the time of this announcement, INTS was trading at $3.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.4M. The 52-week trading range was $3.00 to $15.75. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

INTS - Latest Insights

INTS
Nov 05, 2026, 7:39 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.25
Real-time Price: $2.63 info
Change: -$0.620 (-19%) info
Market Cap: $8.253M info
INTS
Aug 11, 2026, 7:30 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $4.19
Real-time Price: $2.63 info
Change: -$1.56 (-37%) info
Market Cap: $8.253M info
INTS
Aug 11, 2026, 7:17 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.19
Real-time Price: $2.63 info
Change: -$1.56 (-37%) info
Market Cap: $8.253M info
INTS
Jun 16, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.71
Real-time Price: $2.63 info
Change: -$1.08 (-29%) info
Market Cap: $8.253M info
INTS
May 07, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.11
Real-time Price: $2.63 info
Change: -$2.48 (-49%) info
Market Cap: $8.253M info